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cD8+ T-cell repertoire in Older 
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Cytomegalovirus (CMV) infection elicits a strong T-cell immune response, which increases 
further during aging in a process termed “memory inflation.” CMV downregulates the 
expression of HLA-A and HLA-B on the surface of infected cells to limit presentation of 
viral peptides to T-cells although HLA-C is relatively spared as it also engages with inhib-
itory killer immunoglobulin receptor receptors and therefore reduces lysis by natural killer 
cells. We investigated the magnitude and functional properties of CMV-specific CD8+ 
T-cells specific for 10 peptides restricted by HLA-C in a cohort of 53 donors between 
the age of 23 and 91 years. This was achieved via peptide stimulation of PBMCs fol-
lowed by multicolor flow cytometry. Three peptides, derived from proteins generated in 
the immediate-early period of viral replication and restricted by HLA-Cw*0702, elicited 
strong immune responses, which increased substantially with age such that the average 
aggregate response represented 37% of the CD8+ T-cell pool within donors above 
70  years of age. Remarkably, a single response represented 70% of the total CD8+ 
T-cell pool within a 91-year-old donor. HLA-Cw*0702-restricted CD8+ T-cell responses 
were immunodominant over HLA-A and HLA-B-restricted CMV-specific responses and 
did not show features of exhaustion such as PD-1 or CD39 expression. Indeed, such 
CTL exhibit a polyfunctional cytokine profile with co-expression of IFN-γ and TNF-α and 
a strong cytotoxic phenotype with intracellular expression of perforin and granzymeB. 
Functionally, HLA-Cw*0702-restricted CTL show exceptionally high avidity for cognate 
peptide-HLA and demonstrate very early and efficient recognition of virally infected cells. 
These observations indicate that CD8+ T-cells restricted by HLA-C play an important role 
in the control of persistent CMV infection and could represent a novel opportunity for 
CD8+ T-cell therapy of viral infection within immunosuppressed patients. In addition, the 
findings provide further evidence for the importance of HLA-C-restricted T-cells in the 
control of chronic viral infection.
Keywords: cytomegalovirus-specific cD8 T cells, memory inflation, hla-cw*0702, aging, immediate-early antigen
Table 1 | List of cytomegalovirus (CMV) epitopes restricted by HLA-C.
cMV protein amino acid location Peptide sequence hla-c restriction Kinetics of expression reference
pp65 7–15 RCPEMISVL Cw1 L (2)
pp65 341–350 QYDPVAALF Cw4 L (2)
Immediate-early-1 (IE-1) 88–96 QIKVRVDMV Cw6 IE (2)
pp65 198–206 VVCAHELVC Cw8 L (2)
IE-1 305–313 LSEFCRVL Cw0702 IE (34)
IE-1 309–317 CRVLCCYVL Cw0702 IE (11, 30)
UL28 327–335 FRCPRRFCF Cw0702 IE a
UL33 120–128 SYRSTYMIL Cw0702 L a
pp65 294–302 VAFTSHEHF Cw12 L (2)
UL24 120–134 YLCCQTRLAFVGRFV Cw1601 L a
The CMV protein from which the epitope is derived, the amino acid location of the peptide epitope and the HLA-restriction allele are shown. In addition, the kinetics of expression of 
the protein during viral replication is indicated as “immediate early” (IE) or “late” (L). The peptide name is denoted by the first three amino acids of the sequence.
aIdentified by Riddell et al., Fred Hutchinson Cancer Research Centre.2
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inTrODUcTiOn
Human cytomegalovirus (CMV) is a β-herpesvirus with a 
seroprevalence of 60–90% depending on geographical location. 
Although primary infection is typically asymptomatic, the virus 
establishes a state of persistent infection and CMV remains a 
major cause of morbidity and mortality in immunocompromised 
individuals such as the fetus or transplant recipients (1, 2). CMV 
undergoes periodic episodes of reactivation and CD8+ T-cells 
play a critical role in controlling viral reactivation (3–7). Indeed, 
CMV infection triggers one of the largest virus-specific cellular 
immune responses yet determined (8), and an unusual feature is 
that the magnitude of this response increases further with age in 
a process termed “memory inflation” (9–14).
HLA-C is a HLA class I haplotype that is expressed at a lower 
level at the cell surface compared with HLA-A and HLA-B 
(15). HLA-C can present peptides to virus-specific T-cells but 
much less is known about CD8+ T-cell recognition of peptides 
restricted by HLA-C (15, 16). HLA-C surface expression 
is controlled by both transcriptional and posttranslational 
mechanisms (17) and is also negatively regulated by miRNA-
mediated expression (18, 19). Importantly, HLA-C is the 
major ligand for inhibitory killer immunoglobulin receptors 
on natural killer cells (NK  cells) and as such exhibits a dual 
role between NK and T-cell recognition (15, 18). This observa-
tion is likely to explain why virally encoded immune evasion 
proteins which downregulate the expression of most HLA class 
I proteins have evolved to allow relative retention of HLA-C at 
the cell surface to prevent NK recognition of the infected cell. 
The HIV-encoded nef protein exhibits this selective pattern of 
HLA downregulation, and it is noteworthy that polymorphism 
within the HLA-C locus and the presence of HLA-C-restricted 
CD8+ T-cells have are with reduced HIV viral load and slower 
disease progression (19–22). HLA-C-restricted T-cells are 
also important in hepatitis B infection where HLA-Cw0801-
restricted recognition of Env171–180 is associated with viral 
clearance (23).
Almost all studies of CMV-specific CD8+ T-cell immune 
responses have focused on peptides restricted by HLA-A or 
HLA-B (14, 24, 25). However, CMV also encodes a range of 
proteins and RNAs that downregulate the expression of HLA class 
I molecules on infected cells (26–29) although the expression of 
HLA-C is relatively less suppressed (29–32). At the current time, 
relatively little is known regarding the magnitude or function of 
HLA-C-restricted CMV-specific T-cells (11), and these have not 
been studied in older people.
We investigated the magnitude and phenotype of CMV-
specific CD8+ T-cells restricted by HLA-C and investigated 
how these features change during healthy human aging. We 
show that HLA-Cw*0702-restricted CD8+ T-cells specific for 
three peptides derived from the immediate-early (IE) period 
of viral replication expand dramatically with age. These can 
represent up to 70% of the CD8+ T-cell repertoire in people 
over the age of 70 years. These CD8+ T-cells exhibit a polyfunc-
tional IFN-γ+TNF-α+ profile and a strong cytotoxic capacity 
that increases with age. This information provides new insights 
into the mechanism of immune control of CMV infection 
and may also represent novel opportunities for viral-specific 
immunotherapy.
MaTerials anD MeThODs
ethics statement
The recruitment of healthy participants was approved by the 
Solihull ethics committee, study reference; 14/WM/1254. All 
participants were adults aged over 18  years, and written and 
informed consent was taken before participation in accordance 
with the Declaration of Helsinki. This donor cohort included 
samples from healthy laboratory personnel, healthy donors from 
the NHS blood transfusion service, and healthy older adults 
recruited from the “Birmingham 1000 Elders cohort.”
cMV epitopes studied
Novel HLA-C CMV peptide sequences were kindly provided by 
Stanley Riddell2 or obtained from the literature and described 
in Table  1. All peptides were purchased from “Peptide2.0” 
synthesized with crude purity (20–80%), resuspended in 100% 
dimethyl sulfoxide and stored at −20°C. Novel HLA-C peptides 
were identified after coculture of RV798 strain infected fibroblasts 
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with PBMCs from seropositive donors (33). The protein antigens 
to which expanded CD8+ T-cells were specific for were identified 
after coculture with RV798 strains deleted for single CMV genes 
and loss of IFN-γ production (data not shown). The RV798 strain 
of HCMV is based on the AD169 strain backbone but carries a 
deletion of the US2-11 immune evasion proteins (28). The pep-
tide specificity of the CD8+ T-cell clones was determined after 
coculture with COS7 cells transfected with overlapping peptide 
fragments from the determined cognate CMV protein (Riddell, 
unpublished data). The HLA restriction of the peptides was iden-
tified as either HLA-Cw*0702- or HLA-Cw*1601-restricted using 
the SYTHPETHI database. This was subsequently confirmed by 
IFN-γ ELISA (Thermo Scientific) after incubation with EBV-
transformed LCL lines expressing a single HLA allele from the 
donor (HLA-Cw*0702 UL28-derived FRC HLA-restriction data 
provided in Figure S1 in Supplementary Material).
study subjects
33 Young and 20 older healthy CMV-seropositive donors were 
included in this study, defined as <70 or >70  years, respec-
tively. Peripheral blood mononuclear cells were isolated from 
whole blood by density gradient centrifugation (Lymphoprep: 
Nycomed). DNA for MHC class I typing was isolated from the 
isolated PBMCs using the “DNeasy Blood and Tissue Kit” from 
Qiagen according to the manufacturer’s guide. CMV-seropositive 
donors were HLA typed for MHC class I by PCR-based methods 
as previously published (35).
intracellular cytokine secretion  
assay and Flow cytometry analysis
CD8+ T-cells activated by CMV peptides were assessed by 
measuring the production of IFN-γ, IL-2 and TNF-α via flow 
cytometry after PBMC stimulation. PBMCs from seropositive 
donors were peptide-stimulated with 1  µg/mL peptide (final 
concentration) and 1 µg/mL brefeldin A (final concentration) 
for 6 h. Control PBMCs were stimulated with 10 µg/mL (final 
concentration) “Staphylococcus enterotoxin B” or remained 
unstimulated. After incubation, PBMCs were stained with 
LIVE/DEAD Fixable Dead Cell Stain-APC (Invitrogen), CD3-
pacific blue (eBioscience) and CD8-PerCP-Cy5.5 (eBiosci-
ence). Cells were fixed in 4% paraformaldehyde followed by 
permeabilization with 0.5% saponin for 5  min at room tem-
perature (RT) before the addition of IFN-γ-FITC (BioLegend), 
IL-2-PE (BioLegend) and TNF-α-Pe-Cy7 (eBioscience) for 
30 min at RT in the dark. Cells were analyzed on the LSR II 
(BD Biosciences) and data processed on “Kaluza 1.3” software 
(Beckman Coulter). The cytokine polyfunctionality of CMV 
epitope-specific CD8+ T-cells was determined using Boolean 
gating within Kaluza software and analysis using the “Funky 
Cells” software (36). An average of between 200,000 and 
300,000 live lymphocytes events were recorded per sample. 
The percentage of activated, and therefore specific, cytokine 
producing CD8+ T-cells was calculated as a proportion of the 
total CD8+ T-cell population. In all cases, the background 
negative control cytokine production was subtracted from the 
peptide-stimulated tubes.
cMV-specific cD8+ T-cell cloning
Cytomegalovirus peptide-specific IFN-γ producing CD8+ 
T-cell clones were isolated from PBMCs of seropositive donors 
via a limiting dilution assay. PBMCs were peptide-stimulated 
for 3  h, and peptide-specific CD8+ T-cells isolated using the 
“IFN-γ secretion detection” kit (Miltenyi Biotech) according 
to the manufacturer’s instructions. Specific CD8+ T-cells were 
plated onto v-bottom 96 well plates in cloning media [RPMI 
supplemented with 10% fetal calf serum (FCS), 1% human 
serum (HuS), and 1% penicillin/streptomycin (P/S)] at 0.3 
T-cells per well. These were cocultured with γ-irradiated 
PBMCs and HLA-matched and peptide-loaded γ-irradiated 
LCLs and left at 37°C for 14 days at 37°C. At day 3, these were 
supplemented with 60% supernatant from the MLA-144 IL-2-
secreting T-cell line (37) and 100 U/mL IL-2. Expanded wells 
were tested for peptide-specificity by IFN-γ ELISA (Thermo 
Scientific) according to the manufacturer’s instructions after 
O/N coculture with peptide-loaded HLA-matched LCLs. 
Epitope-specific CD8+ T-cell clones were expanded in vitro in 
T-cell media (RPMI, 30% MLA, 10% FCS, 1% HuS, and 1% P/S) 
and restimulated with peptide-pulsed γ-irradiated LCLs and 
PBMCs every 21 days.
The avidity of CD8+ T-cell clones was determined by 
overnight coculture of 1,000 CD8+ T-cells and 1 ×  104 LCLs 
per well on a v-bottom 96 well plate with a gradient peptide 
concentration in RPMI (supplemented with 10% FCS and 
1% P/S) ranging from 50 µM (10−5) to 50 pM (10−11). Positive 
recognition of the peptide gradient was determined by IFN-γ 
ELISA (Thermo Scientific) according to the manufacturer’s 
instructions.
The avidity of HLA-Cw*0702-restricted CD8+ T-cells within 
donor PBMC was determined as previously described (38). 
Briefly, 50,000 PBMCs were incubated for 16  h with a peptide 
gradient ranging from 50 µM (10−5) to 50 pM (10−11), and peptide-
specificity was determined by intracellular cytokine staining for 
TNF-α. The EC50 of the HLA-Cw*0702-restricted PBMC and 
CD8+ T-cell clones was determined in GraphPad Prism 6 by 
applying a sigmoidal dose response variable slope.
cD8+ T-cell recognition of cMV-infected 
Fibroblasts
MRC5 (HLA-Cw*0702+) were purchased from ATCC and 
maintained in DMEM media supplemented with 10% FCS, 
1% P/S, and 1% glutamine (Q). 1 × 104 fibroblasts/well were 
then infected with the AD169 CMV strain at an MOI of 5 
and left for 6–72 h at 37°C. At the relevant time point, 10,000 
epitope-specific CD8+ T-cell clones were added per well, and 
CD8+ T-cell recognition of peptide measured by IFN-γ ELISA 
after 16 h.
statistics
All statistics were computed in GraphPad Prism 6 using non-
parametric tests. Specific tests are indicated in figure legends. 
Statistical significance was defined as * as p-value of <0.05, 
**<0.01, ***<0.001.
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resUlTs
cMV Peptides synthesized in the ie Period 
of Viral replication and restricted by 
hla-cw*0702 stimulate strong cD8+ 
T-cell immune responses Which increase 
Markedly with age
To determine the magnitude of the CMV-specific HLA-C-
restricted CD8+ T-cell response, we initially studied 10 peptides 
restricted through different HLA-C alleles (Table 1). To the best 
of our knowledge, these epitopes represent all currently defined 
CMV HLA-C-restricted epitopes. Four peptides were derived 
from the immediate-early-1 (IE-1) protein and one from the 
UL28 protein, both of which are synthesized in the IE period 
of viral replication. By contrast, six epitopes were derived from 
pp65, UL33, or UL24, which are generated in the “late” stage of 
viral replication (Table 1).
A panel of 53 healthy CMV-seropositive donors aged 
23–91 years was screened for peptide responses using intracel-
lular cytokine staining (Table 1 and Figure 1A; Figures S3 and 
S4 in Supplementary Material). The number of IFN-γ, TNF-α, 
or IL-2-positive CD8+ T-cells was then expressed as a percentage 
of the total CD8+ T-cell pool (Figure 1A, gating strategy Figure 
S2 in Supplementary Material). To examine if the magnitude of 
immune response was influenced by donor age, we then compared 
responses within donors aged below or above the age of 70 years. 
Donors were screened for peptide responses if they expressed the 
relevant HLA allele of the peptide in question.
CD8+ T-cell responses to peptides restricted by HLA alleles 
HLA-Cw1/4/6/8/12/16 ranged between 0.02 and 14.2% (Figure S4 
in Supplementary Material). A single large response was detected 
in a donor of 86 years toward the HLA-Cw*1601-restricted YLC 
peptide (Figure S4 in Supplementary Material). By contrast, strik-
ing TNF-α and IFN-γ CD8+ T-cell responses were observed to 
three peptides restricted by HLA-Cw*0702 (FRC, CRV, and LSE, 
Table 1), and these became the focus of further studies in this 
report (Figure 1A).
FRC-specific responses were found in 74% (32/43) of 
HLA-Cw*0702+ donors (Figure  1A), and the TNF-α response 
increased from an average of 2.4% of the total CD8+ T-cell pool in 
donors <70 years to an average of 16.7% in donors above this age 
(Figure 1B). The IFN-γ production increased similarly from 2.5 to 
14.9% while IL-2 responses were low and increased slightly from 
0.2 to 0.9%, respectively (Figure S3 in Supplementary Material). 
Remarkably, the IFN-γ and TNF-α responses against this peptide 
comprised 63 and 70% of the peripheral CD8+ T-cell repertoire 
respectively in the eldest donor aged 91 years (Figure 1C).
Peptides CRV (39) and LSE (34) are derived from the IE-1 
protein and also elicited strong CD8+ T-cell immunity which 
increased in relation to the age of the donors (Figures  1A,B). 
Specifically, CRV- and LSE-specific responses ranged from 0.01 
to 32.7% and from 0.01 to 16.7% of the total CD8+ T-cell response 
and were detected within 80 and 76% of individuals (20/25 and 
16/21), respectively (Figure  1A). The average TNF-α response 
to CRV increased from 2.7% in donors <70  years to 13.6% of 
the CD8+ T-cell repertoire in those aged >70 years (Figure 1B). 
Corresponding average TNF-α values for LSE-specific responses 
increased from 0.8 to 7.7% between these two age groups 
(Figure 1B). As with FRC-specific responses, the IFN-γ response 
to peptide stimulation also increased with age while IL-2 responses 
remained comparatively low (Figure S3 in Supplementary 
Material). Interestingly, CD8+ T-cell responses against the SYR 
peptide derived from the UL33 protein, expressed at a late stage 
in viral replication (Figure  1A), were relatively weak. TNF-α 
responses to this HLA-Cw*0702-restricted peptide ranged from 
0.05 to 1% of the total CD8+ T-cell pool (Figure 1A: IFN-γ and 
Il-2 responses in Figure S3 in Supplementary Material).
A cross-sectional profile of CD8+ T-cell responses against the 
FRC, CRV, and LSE peptides in relation to age revealed a strong 
“inflationary” profile (Figures  1C,D) with the most dramatic 
responses seen in donors aged over 70  years (Figure  1D). As 
such, this work shows that strong and “inflationary” CD8+ 
T-cell immune responses are observed against three peptides 
synthesized in the IE period of viral replication and presented 
through HLA-Cw*0702. Therefore, both the temporal generation 
of the epitope and allelic restriction are important determinants 
of the immunodominance of the CMV-specific immune response 
restricted by HLA-C.
The aggregate response to 
immunodominant cMV Peptides 
restricted by hla-cw*0702 can 
represent over 70% of the cD8+ T-cell 
repertoire in Older People
To determine the total proportion of the CD8+ T-cell repertoire 
that was represented by HLA-Cw*0702-restricted responses, we 
combined individual donor peptide responses to determine the 
total aggregate response against the three epitopes (Figure 2B). 
The combined TNF-α CD8+ T-cell response ranged from 0.31% 
of the CD8+ T-cell repertoire in a 25-year-old donor to 70.3% 
in the oldest donor of 91 years (Figures 2B,C). IFN-γ responses 
were comparable whereas IL-2 responses ranged from 0.13 to 
11.1% (data not shown). Responses against all three peptides 
were maintained in most donors, although FRC-specific CD8+ 
T-cells became the most dominant population within the two 
oldest donors aged 88 and 91 years (Figure 2B).
Importantly, simultaneous stimulation of PBMC from three 
donors aged 32–81 years with all three HLA-Cw*0702-restricted 
peptides in combination detected a similar response to the sum 
of the three individual peptide stimulations, indicating that these 
responses are not cross-reactive (representative donors shown 
Figure  2A). This feature was further confirmed by the failure 
of peptide-specific clones to respond to stimulation with the 
alternate epitopes (data not shown).
inflation of hla-cw*0702-restricted  
cD8+ T-cell responses with age is 
apparent in Prospective studies  
within individual Donors
In addition to the finding of memory inflation of HLA-
Cw*0702-restricted responses in the cross-sectional analysis 
FigUre 1 | CD8+ T-cell response after stimulation by cytomegalovirus (CMV) peptides restricted by HLA-Cw*0702. (a) The magnitude of CD8+ T-cell TNF-α 
production in response to peptide stimulation in HLA-Cw*0702+ CMV-seropositive donors. Peptide-specific CD8+ T-cells were identified after peptide stimulation 
and intracellular cytokine staining. Each symbol represents the percentage of an individual donor’s total CD8+ T-cell pool producing TNF-α in response to the 
peptide. The peptide name and temporal pattern of expression during the viral lifecycle are shown on the x-axis. Horizontal lines represent the mean. (b) The 
magnitude of CD8+ T-cell TNF-α production in response to peptide stimulation in HLA-Cw*0702+ CMV-seropositive donors aged <70 or >70 years of age. 
Peptide-specific CD8+ T-cells were identified as in panel (a). Each symbol represents the percentage of an individual donor’s total CD8+ T-cell pool producing TNF-α 
in response to the peptide. Gray circles represent donors <70 years of age, and black circles represent donors >70 years of age. Horizontal lines represent the 
mean. Statistical significance was determined by Mann–Whitney within GraphPad Prism 6 (*p < 0.05 and ***p < 0.001). (c) Representative plots of CD8+ T-cell 
cytokine production in six donors following stimulation with FRC peptide. FRC-specific CD8+ T-cells were identified as in panel (a) to assess IFN-γ (top row) and 
TNF-α (bottom row) production. CD8 expression is shown on the y-axis and cytokine expression on the x-axis. The age of the donor is provided  
above the representative plots. The gating strategy is provided in Figure S2 in Supplementary Material. (D) Magnitude of cytokine production following stimulation 
with peptides FRC, CRV, and LSE shown in donors according to age. Peptide-specific CD8+ T-cells were identified as in panel (a). The age of the donors in years  
is shown on the x-axis, and the percentage of the total CD8+ T-cell cytokine response is provided on the y-axis. Significance was calculated by Spearman’s rank 
correlation.
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FigUre 2 | CD8+ T-cell responses against cytomegalovirus (CMV) peptides restricted by HLA-Cw*0702 are not cross-reactive, and their aggregate response 
represents a large percentage of the total CD8+ T-cell repertoire within older donors. (a) CMV-specific T-cell responses to different peptides do not show evidence 
of cross reactivity. PBMC from a CMV-seropositive donor aged 81 years was stimulated with either FRC (left), CRV (middle), LSE peptide (right), or all three 
peptides (far right) before intracellular cytokine staining for IFN-γ (top row) and TNF-α production (bottom row). (b) Distribution of individual peptide-specific CD8+ 
T-cell responses producing TNF-α within 16 donors. The TNF-α response to each peptide stimulation is shown as a percentage of the total CD8+ T-cell repertoire 
within individual donors (y-axis). The age of the donor in years is shown on the x-axis. One donor is included at subsequent time points (88 and 91 years) indicated 
by *. (c) Total magnitude of CMV-specific CD8+ T-cell response restricted by HLA-Cw*0702 within individual donors. Each circle represents the aggregate of the 
FRC, CRV, and LSE-specific CD8+ T-cell responses within individual donors as identified in panel (a). White circles represent donors <70 years of age, and black 
circles represent donors >70 years of age. Lines represent mean, and significant difference was determined using Mann–Whitney tests in GraphPad Prism 6 
(***p < 0.001).
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of the donor cohort, we were also interested to see if CD8+ 
T-cell responses were found to increase in prospective stud-
ies within donors (representative FRC-specific CD8+ T-cell 
TNF-α responses provided in Figure  3A). Blood samples 
were available from nine HLA-Cw*0702-positive donors 
at time points between 1 and 10  years apart. A significant 
increase in the CD8+ T-cell pool response to the three HLA-
Cw*0702-restricted peptides was observed during follow up 
(Figure  3B). For two donors where four time points were 
available, fluctuations were observed but the percentage of 
HLA-Cw*0702-restricted CD8+ T-cells were significantly 
increased over an 8- or 10-year period compared with the 
initial measurement (Figures  3B,C). The most dramatic 
increases were observed in donors aged >70 years where, for 
example, an FRC-specific response comprising 31% of the CD8+ 
T-cell pool in an 86-year-old donor expanded to 63% over a 
period of 5 years (Figures 3A,C; Figure S5 in Supplementary 
Material).
FigUre 3 | Continued
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FigUre 4 | The pattern of co-expression of IFN-γ, TNF-α, and Il-2 cytokines within HLA-Cw*0702-restricted cytomegalovirus-specific CD8+ T-cells. Co-expression 
of the three cytokines was determined within CD8+ T-cells following stimulation with peptide. The co-expression of IFN-γ, IL-2, and TNF-α by the total FRC (top left), 
CRV (top right) and LSE-specific CD8+ T-cell populations (bottom left) and total HLA-Cw*0702 CD8+ T-cell responses (bottom right) observed within all donors are 
represented. Donors were assigned into two groups based on age <70 or >70 years. The different combinations of IFN-γ, IL-2, and TNF-α co-expression are 
indicated on the x-axis. Combinations were calculated using the Boolean gating strategy in Kaluza 1.3 software, and percentages were generated using the funky 
cells software (36). The Boolean gating strategy is provided in Figure S8 in Supplementary Material. Statistical significance was tested by Kruskal–Wallis test with 
Dunn’s corrections applied in GraphPad Prism 6.
FigUre 3 | Memory inflation of HLA-Cw*0702-restricted T-cell responses is seen within individual donors. (a) Example of memory inflation within donors. 
FRC-specific CD8+ T-cell responses were followed within nine donors using blood samples taken between 1 and 10 years apart. This figure shows the TNF-α 
response in three donors at the initial and final time points. Percentages represent the TNF-α response to peptide as a proportion of the total CD8+ T-cell repertoire. 
The same number of lymphocytes is demonstrated in the two representative plots at each time point per donor. [Additional time points are provided in panel  
(c).] (b) Summary of longitudinal analyses of peptide-specific CD8+ T-cell responses. The initial and last time points (after 1–10 years) for each HLA-Cw*0702-
restricted CD8+ T-cell response are shown for all nine donors. Statistical significance was determined by a paired Wilcoxon test. (c) Representation of all  
prospective peptide-specific T-cell responses at individual time points within each donor.
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hla-cw*0702-restricted cD8+ T-cells 
Demonstrate a cytotoxic Phenotype 
Which increases Further during aging 
without evidence of exhaustion
Expression of polyfunctional capacity by CD8+ T-cells is 
associated with enhanced antiviral activity (40, 41). Therefore, 
we next examined the pattern of cytokine co-expression by 
HLA-Cw*0702-restricted CD8+ T-cells in younger and older 
donors (gating strategy Figure S8 in Supplementary Material). 
The majority of T-cells exhibited simultaneous production of 
both IFN-γ and TNF-α, and this proportion increased from 
54.7% in younger donors to 73.5% in older people although 
this did not reach statistical significance (Figure  4). An 
important observation was a decrease in T-cells secreting 
either IFN-γ or TNF-α alone and a notable reduction in the 
proportion of IL-2 secreting cells (Figure 4). This is likely to 
reflect the acquisition of an increased polyfunctional effector 
profile during differentiation and clonal expansion in associa-
tion with age (42, 43).
Cytotoxic capacity was next determined by the intracellular co-
expression of perforin and granzymeB (Figure 5A). Dual expres-
sion increased from 18.4, 21.2, and 29.3% of FRC-, CRV-, and 
LSE-specific T-cells respectively in a 31-year-old donor to 99.2, 
99, and 97.3% in a donor of 88 years (Figure 5A). To investigate 
the potential regulation of cytotoxic cells, we also determined the 
pattern of PD-1 and CD39 expression that have been associated 
with an exhausted phenotype on some populations of virus-
specific CD8+ T-cells (44, 45). PD-1 expression was seen to vary 
markedly between individuals, with a range of 0.44–65.4%, and 
the number of PD-1+ cells decreased during aging (Figure 5B). 
CD39 expression was low on CMV-specific CD8+ T-cells, in line 
with previous reports, and this was observed even within donors 
aged up to 91 years. Of note, this was observed despite the fact that 
CD39 expression was observed on a large proportion of the total 
CD8+ T-cell population (Figure S7 in Supplementary Material).
FigUre 5 | Cytotoxic and differentiation phenotype of HLA-Cw*0702-
restricted cytomegalovirus (CMV)-specific CD8+ T-cells in relation to age.  
(a) HLA-Cw*0702-restricted CMV-specific CD8+ T-cells were identified after 
peptide stimulation followed by intracellular cytokine staining for TNF-α. 
Intracellular dual expression of perforin and granzymeB was then determined 
by flow cytometry. R values: FRC = 0.79, CRV = 0.90, LSE = 0.72, and 
Average = 0.87. (b) CMV-specific cells were identified as in panel (a) and 
examined for surface expression of PD-1. R values: FRC = -0.47, 
CRV = −0.43, LSE = −0.2, and Average = −0.25. Values are shown for each 
individual peptide response (FRC—black circle and black line; CRV—black 
squares and gray line; LSE—white circles and broken line) and also for the 
aggregate values of all HLA-Cw*0702-restricted cells (solid red line). Lines 
represent linear regression, and statistical significance was obtained by 
Spearman’s rank correlation in GraphPad Prism 6 (*p < 0.05, **p < 0.01, and 
***p < 0.001). (c) HLA-Cw*0702-restricted CD8+ T-cells were identified as in 
panel (a). The differentiation status of the epitope-specific CD8+ T-cell 
responses was then analyzed using CD27 vs CD28 expression. Statistical 
significance was determined by Mann–Whitney test in GraphPad Prism 6 
(**p < 0.01 and ***p< 0.001).
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Loss of CD27 and CD28 is observed on late-differentiated 
memory cells, and the pattern of CD27 and CD28 co-expression 
was therefore used to contrast the pattern of differentiation 
of CD8+ T-cells between young and older individuals (46). 
Interestingly, CD27 and CD28 expression was lost on the major-
ity of HLA-Cw*0702-restricted T-cells within older individuals 
(ranges 41.0–96.3%) whereas CD27+CD28+ populations became 
much less common (Figure 5C).
These data indicate that HLA-Cw*0702-restricted CMV-
specific CD8+ T-cells become more differentiated during aging 
but remain highly functional and do not develop evidence of 
cellular “exhaustion.”
hla-cw*0702-restricted cMV-specific 
cD8+ T-cells exhibit Very high avidity  
with age and recognize infected cells  
for up to 72 h after infection
The avidity of CD8+ T-cells for their HLA-peptide target can be 
used as a correlate of antiviral efficacy (47) and is an important 
determinant of memory inflation within CMV-specific CD8+ 
T-cells (48–50).
We next analyzed the functional avidity of HLA-Cw*0702 
CD8+ T-cells within donor PBMC through measurement of 
the peptide concentration that induced 50% maximal cytokine 
production (EC50). PBMC from three young (<70  years) and 
three elderly (>70 years) donors was incubated with peptide for 
16 h followed by detection of intracellular TNF-α (Figure 6A). 
Peptide-specific CD8+ T-cells from elderly donors were found to 
display higher avidity than those from younger donors (average 
EC50 of younger donors 0.5 µg or 10−7.1 log10M FRC and 0.00125 µg 
or 10−9.7 log10M CRV, Figure 6B) (Figure 6A).
12 FRC-specific and 5 CRV-specific CD8+ T cell clones were 
also generated, and functional avidity was assessed in these cells. 
EC50 values ranged between 0.5 and 50 pg (10−9–10−11 log10M), 
with an average of 5 pg (10−10 log10M), demonstrating very high 
clonal avidity for both FRC-specific and CRV-specific clones 
(Figure 6C).
We also assessed the time course of peptide recognition by 
HLA-Cw*0702-restricted T-cells through incubation of FRC-
specific and CRV-specific T-cell clones with virus-infected target 
cells. T-cell recognition peaked at 6–12  h after infection and 
was retained until 72 h (Figure 6D). HLA-Cw*0702-restricted 
T-cells therefore have the capacity to recognize their cognate IE 
peptide epitopes very early during viral infection. These findings 
suggest that the combination of high avidity and extended period 
of peptide recognition may serve to drive the relative expansion 
of HLA-Cw*0702-restricted CD8+ T-cells during viral reactiva-
tion events.
DiscUssiOn
Virus-specific CD8+ T-cells restricted by HLA-C have received 
considerably less investigation than responses restricted by 
HLA-A or HLA-B. Here we have shown that CD8+ T-cells specific 
for peptides derived from proteins expressed in the IE phase of 
CMV replication and restricted by HLA-Cw*0702 elicit potent 
CD8+ T-cell responses. Moreover, these accumulate markedly 
with age such that they represent over half of the CD8+ T-cell 
repertoire in older people. As such, we believe these to be the larg-
est CD8+ T-cell responses ever reported in the human immune 
system.
Cytomegalovirus infection is most commonly acquired during 
the first year of life, and although infection can also be acquired 
in adulthood, it is likely that most of the majority of our donors 
had carried chronic infection for many decades. Importantly, 
we were able to detect an increase in the magnitude of CD8+ 
T-cell responses within individual donors over time indicating 
that “memory inflation” was not simply a cohort effect and is, to 
the best of our knowledge, the first prospective demonstration 
FigUre 6 | Continued
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of memory inflation within humans. A range of studies suggest 
that memory inflation is driven by an increase in CMV viral 
load and it was noteworthy that viral copy number increased 
from 200 to 400 copies/25  ng DNA from CD14+ monocytes 
within a period of 5 years in our oldest donor aged 91 years. This 
coincided with an increase in the FRC-specific CD8+ T-cell pool 
from 2.7 to 37%, indicating that CD8+ T-cell memory inflation 
was proportionally much greater than the increase in viremia. As 
such, the quantitative relationship between peripheral viral load 
and CMV-specific CD8+ T-cell response is unclear, and one fac-
tor may relate to the relative presentation of viral antigen within 
secondary lymphoid tissue.
The magnitude of the HLA-Cw*0702-restricted CMV-specific 
immune response is further support for the idea that virus-
specific cells explain the association between persistent CMV 
infection and an increase in the size of the total memory T-cell 
pool (51) and inversion in the CD4:CD8 ratio (52). However, the 
magnitude of memory inflation varied within individual donors 
in line with previous studies. The determinants of memory 
inflation are not yet clearly established but could include the 
magnitude of the initial viral inoculum (53) and the frequency 
and magnitude of episodes of subclinical viral reactivation. 
Indeed, subclinical episodes of viral reactivation can be sup-
pressed by T-cells before infectious virions are produced (54, 
FigUre 6 | HLA-Cw*0702-restricted CD8+ T-cells have high avidity and recognize cells in the immediate-early time point of viral infection. (a) TNF-α production by 
PBMCs in response to HLA-Cw*0702-restricted peptide gradient. 50,000 PBMCs were incubated with peptide concentration of 50 pg (10−11) to 50 µg (10−5) in the 
presence of brefeldin A followed by intracellular cytokine staining for TNF-α. The EC50 was defined as the peptide concentration that induced the 50% maximal 
TNF-α production by HLA-Cw*0702-restricted CD8+ T-cells as a percentage of the total CD8+ T-cell population. Percentages represent the percentage of the total 
CD8+ T-cell pool responding to that concentration of HLA-Cw*0702-restricted peptide. The two highest (50 and 5 µg) and two lowest (500 and 50 pg) peptide 
concentrations are shown as representative examples. (b) Functional avidity of HLA-Cw*0702-restricted cytomegalovirus (CMV)-specific PBMC. 50,000 PBMCs 
from three young (32, 46, and 56 years) and three elderly donors (83, 91, and 91 years) were incubated with peptide concentrations of 50 pg (10−11) to 50 µg (10−5), 
and the EC50 was defined as in panel (a). This was determined within GraphPad Prism 6 by applying a sigmoidal dose response curve. Percentages represent the 
percentage of the total CD8+ T-cell pool responding to that concentration of HLA-Cw*0702 peptide. Younger donors (<70 years) are represented by dashed lines, 
and older donors (>70 years) represented by solid black lines. Lines represent the average percentage of PBMCs responding to that peptide gradient (FRC—left 
graph and CRV—right graph) within n = 3 donors per age group. (c) Functional avidity of HLA-Cw*0702-restricted CMV-specific CD8+ T-cell clones. CD8+ T-cell 
clones were isolated by limiting dilution analysis from HLA-Cw*0702+ CMV-seropositive donors. 1,000 CD8+ T-cell clones were cocultured for 16 h with 5 × 104 
peptide-pulsed LCL loaded with a peptide concentration gradient of 50 pg (10−11) to 50 µg (10−5). CD8+ T-cell activation was analyzed by IFN-γ ELISA. n = 12 clones 
for FRC and n = 5 for CRV. The EC50 was determined as in panel (b). The red line represents the average EC50 avidity of the CD8+ T-cell clones. (D) Time course of 
recognition of HLA-Cw*0702-restricted CMV peptides during viral infection. The presentation of HLA-Cw*0702-restricted peptides during CMV infection was 
determined by recognition by virus-specific T-cell clones following infection of MRC5 fibroblasts (HLA-A2+HLA-Cw*0702+) in vitro. 10,000 CD8+ T-cells were 
cocultured with the infected fibroblasts, and IFN-γ ELISA was used to measure peptide recognition at the indicated time points. Left graph = FRC-specific T-cell 
clones and right graph = CRV-specific T-cell clones. n = 3–6 per time point and n = 3 clones tested per specificity. ui, uninfected cells; peptide, target cells pulsed 
with cognate peptide. Target cells were infected with AD169 virus at an MOI of 5. The peptide-pulsed control bar represents the average of all experiment replicates.
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55) and abortive viral reactivation with expression of IE genes 
in the absence of early or late genes is observed in murine CMV 
infection (56). It is therefore significant that the three peptides 
that drive HLA-Cw*0702-restricted memory inflation are all 
derived from proteins synthesized in the IE phase of viral rep-
lication (57). In this regard, it is noteworthy that we observed 
only modest non-inflationary CD8+ T-cell responses to the HLA-
Cw*0702-restricted UL33-derived SYR peptide that is generated 
in the late phase of replication. Several studies have now identi-
fied that the expression kinetics of CMV peptides determines 
their immunodominance and capacity to drive CD8+ T-cell 
inflation (57–60). Indeed, HSV-1 epitopes induce inflationary 
CD8+ T-cell populations when expressed under the influence of 
CMV promoters with IE kinetics whereas those linked to non-IE 
promoters do not (57).
HLA-C alleles are relatively protected from HLA downregu-
lation following viral infection (20, 31, 32), and this is likely 
to be a factor driving the memory inflation observed in our 
work (31, 61). Proteomic analysis of CMV-infected fibroblasts 
revealed downregulation of HLA-A and HLA-B proteins by 
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24  h while HLA-C expression started to decline only at 72  h 
(32). An important observation is that it was the HLA-Cw*0702 
allele that was specifically associated with substantial memory 
inflation. The HLA-Cw*0702 protein is relatively resistant to 
downregulation by US2-11 proteins due to polymorphism 
within the α3 domain and C terminus (30). Interestingly, 
expression of HLA-Cw*0702 is also relatively protected fol-
lowing adenovirus infection where it plays an important role 
in engaging the inhibitory protein KIR2DL3 on NK cells (62). 
As such, this allele may play a particularly critical role in sup-
pression of NK recognition during CMV infection and could 
permit the generation of substantial cytotoxic HLA-Cw*0702-
restricted T-cell responses. However, we cannot speculate that 
relative resistance of HLA-Cw*0702 to US2-11 proteins is the 
sole factor and other HLA-C alleles may also exhibit similar 
properties. We also investigated if the expression of HLA-C 
increases with age and did observe a non-significant trend in 
the intensity of DT9-staining on monocytes in older people 
(data not shown). As such, this may be an additional factor that 
drives HLA-C-restricted CD8+ memory inflation although the 
full biological significance is currently unclear.
A further noteworthy characteristic of HLA-Cw*0702-
restricted T-cells is their very high avidity for cognate peptide-
HLA, and this was seen to increase substantially between younger 
and older donors. Functional avidity is critical in determining 
clonal dominance of peptide responses during chronic infection 
(49, 63), and the lower surface expression of HLA-C expression 
compared with HLA-A or HLA-B may act to select for T-cells 
with high-affinity TCR. Furthermore, immunodominance of 
CD8+ T-cells is determined by competition for cognate peptide 
on target cells (49, 63), and expanded HLA-Cw*0702-restricted 
responses might therefore be expected to limit the expansion 
of T-cells restricted through HLA-A or HLA-B alleles. We did 
indeed find that HLA-Cw*0702-restricted responses were larger 
than the combined response to a range of immunodominant 
peptides presented through HLA-A and HLA-B alleles (Figure S6 
in Supplementary Material). Interestingly, expanded populations 
of low-avidity HLA-A-restricted CMV-specific CD8+ T-cells 
accumulate in many older individuals (64) and may perhaps 
indicate a relative shift in the importance of HLA-A/B and HLA-
C-restricted T-cells in the control of CMV reactivation across 
the human life course. An extension of this argument might be 
that persistent viral infections have served to act as an important 
selective pressure for the evolution of HLA-C to maintain lifelong 
viral control.
Frequent stimulation of viral-specific CD8+ T-cells by chronic 
exposure to antigen can lead to cellular dysfunction and “exhaus-
tion” (39). Despite this, CMV-specific CD8+ T-cells generally 
retain functional activity within older donors (41, 65), and this 
pattern was observed for HLA-Cw*0702-restricted responses 
which exhibited a potent Th1 cytokine and cytotoxic phenotype. 
Indeed, these phenotypic features increased further during aging 
with no increase in PD-1 (66) or CD39 expression (45).
Adoptive therapy with T-cells specific for peptides restricted 
by HLA-A or HLA-B alleles is effective in control of viremia 
in immune suppressed individuals, and the unique properties 
of HLA-Cw*0702-restricted CD8+ T-cells suggest that they 
could also have potential for immunotherapy (3, 67–69). The 
HLA-Cw*0702 allele has a population prevalence of 15–20% in 
different ethnic groups, and IE-specific T-cells are effective in 
controlling CMV reactivation events in both humans and mouse 
models (70, 71). Furthermore, CMV reactivation following 
hemopoietic stem cell transplantation leads to upregulation of 
HLA-C expression on many different cell types and the potential 
utility of HLA-C-restricted T-cells for cellular immunotherapy 
therefore deserves further investigation (72).
Given the unprecedented magnitude of HLA-Cw*0702-
restricted CD8+ T-cells in older individuals, it is also important 
to consider if this may lead to any detrimental effects such as 
immune senescence (73), vascular disorders (74), and reduced 
survival (52, 75–77). As such, although expansion of HLA-C-
restricted CD8+ T-cells appears effective in controlling clinical 
CMV reactivation in older people, it is also possible that they may 
also play a detrimental role in some settings.
In conclusion, our work demonstrates that CMV-specific 
CD8+ T-cells that are restricted by HLA-Cw*0702 expand enor-
mously during healthy aging and come to dominate the memory 
CD8+ T-cell pool in older people. These findings contribute to 
growing appreciation of the importance of HLA-C in the control 
of chronic viral infections and indicate that further attention 
should be given to the physiological and therapeutic role of HLA-
C-restricted CD8+ T-cells.
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